ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2018, Vol. 10 ›› Issue (1): 31-35.doi: 10.3969/j.issn.1674-3865.2018.01.009

• 临床研究 • 上一篇    下一篇

复方丹参注射液辅助治疗小儿过敏性紫癜Meta分析

孙丽平,王雪姣   

  1. 130021 长春，长春中医药大学附属医院儿科(孙丽平)；130117 长春，长春中医药大学2014级中医儿科学专业研究生（王雪姣）
  • 出版日期:2018-02-25 发布日期:2018-03-23
  • 通讯作者: 孙丽平，E-mail：slpwzt7063@163.com
  • 作者简介:王雪姣（1990-），女，长春中医药大学2014级硕士研究生在读，医师。研究方向：中医药防治小儿肺系疾病

Meta-analysis of compound Danshen injection in adjuvant therapy of Henoch-Schonlein purpura in children

SUN Liping，WANG Xuejiao   

  1. Pediatric Department of Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021,China
  • Online:2018-02-25 Published:2018-03-23

PDF (PC)

161

摘要：
目的
系统评价复方丹参注射液辅助治疗过敏性紫癜的临床疗效及安全性。
方法
计算机检索PubMed、WEB of SCIENCE、The Cochrane Library、CNKI、VIP、WanFangData，收集所有关于复方丹参注射液治疗过敏性紫癜的随机对照试验，检索时限为建库至2016年11月30日。两位研究者按纳入与排除标准筛选文献、提取资料，按Cochrane系统评价的方法评价纳入研究的质量，采用RevMan 5.3软件进行Meta分析。
结果
共纳入10项随机对照试验，共计768例患儿。结果显示，复方丹参注射液辅助治疗过敏性紫癜在总有效率、皮疹消退时间、关节症状缓解时间及消化道症状缓解时间等方面均优于常规治疗组，差异有统计学意义(P<0.05)。未报道复方丹参注射液治疗过敏性紫癜的严重不良反应。
结论
复方丹参注射液辅助治疗小儿过敏性紫癜疗效确切，无明显不良反应，值得临床推广。但纳入研究的文献质量低，其疗效需要高质量临床试验来验证。

关键词: 过敏性紫癜, 复方丹参注射液, Meta分析, 儿童

Abstract:
Objective
To evaluate the efficacy and safety of compound Danshen injection for Henoch-Schonlein purpura(HSP).
Methods
Clinical randomized controlled trials(RCT) were collected by searching Pubmed, WEB of SCIENCE, the Cochrane Library, CNKI, VIP and Wanfang Data from their inception to November 30, 2016. Two researchers screen the literatures and selected the data according to inclusion and exclusion criteria. The quality of included studies was assessed according to the criteria recommended Cochrane Collaboration. Meta-analysis was performed by using RevMan 5.3 software.
Results
Ten trials(n=768) were included. The results of Meta-analysis demonstrated that, the efficiency of compound Danshen injection adjuvant therapy for HSP was better, including the total effective rate, the time of erythra regression time, the relief time of clinical symptoms of joints and the relief time of clinical gastrointestinal symptoms(P<0.05); there were no serious adverse effects in the treatment.
Conclusion
Compared with routine treatment, compound Danshen injection therapy might be a better choice for HSP with more remarkable efficacy and few adverse effects. However, the quality of the included literature is low, so high-quality clinical trials are needed to verify its effect.

Key words: Henoch-Schonlein purpura, Compound Danshen injection, Meta-analysis, Children